---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-068425"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-10-30T11:06:12+00:00"
generated_at: "2026-10-30T11:10:05.122733+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Acumen's Phase 2 ALTITUDE-AD fails primary endpoint; sabirnetug development halted, cash conservation planned

## Summary
- Phase 2 ALTITUDE-AD missed the primary iADRS endpoint at 18 months vs placebo at both the 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints were not significant.
- Sabirnetug was generally well tolerated; ARIA-E occurred in ~10% of treated participants; PET SUVr showed statistically significant amyloid plaque reduction at weeks 36 and 76.
- Acumen plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD, and to implement cash conservation measures.
- Company will evaluate strategic options, including its Enhanced Brain Delivery (EBD) program, to maximize shareholder value.
- Additional fluid biomarker and imaging data expected in coming weeks, though Acumen does not expect it to change the trial's efficacy conclusions; CEO Daniel O'Connell commented.

## SEC filing metadata
- accession: 0001628280-26-068425
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-10-30T11:06:12+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026068425/0001628280-26-068425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026068425/abos-20261030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-068425
- JSON: https://secwatch.observer/filing/0001628280-26-068425.json
- Plain text: https://secwatch.observer/filing/0001628280-26-068425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.